FEMASYS Business Summary

Femasys Inc. (FEMY) is a commercial-stage biomedical company specializing in minimally invasive, in-office therapeutic and diagnostic solutions for women’s healthcare. The company generates revenue primarily through the direct sale and distribution of medical devices across three core segments: infertility (FemaSeed), permanent birth control (FemBloc), and diagnostics (FemVue and FemCerv). As of February 2026, Femasys is aggressively scaling its commercial footprint, leveraging a hybrid model of direct U.S. sales and international partnerships, such as its recent expansion into Switzerland. The company competes directly with established players like CooperSurgical, Daré Bioscience, and Insightec, positioning itself as a disruptive provider of non-surgical, non-hormonal alternatives that reduce the total cost of care by shifting procedures from hospitals to physician offices. Femasys is led by Founder, President, and CEO Kathy Lee-Sepsick, an industry veteran with over 20 years of experience in medical device innovation and commercialization. The executive team includes Chief Financial Officer Dov Elefant, who oversees the company’s capital strategy and recent financing rounds, and Chief Technology Officer Jeremy Sipos, who leads the R&D and intellectual property portfolio. In mid-2025, the company strengthened its commercial leadership by appointing Kelley Nicholas as Chief Commercial Officer to drive global market penetration. The board is chaired by Charles Larsen and includes notable independent directors such as Alistair Milnes and Joshua Silverman. Institutional backing remains significant, with major positions held by Dauntless Investment Group, Vanguard Group, and BlackRock, reflecting continued investor confidence in the company’s late-stage clinical pipeline and commercial ramp-up.